182 related articles for article (PubMed ID: 28978007)
1. Differences in risk factors of malignancy between men and women with type 2 diabetes: A retrospective case-control study.
Dąbrowski M; Szymańska-Garbacz E; Miszczyszyn Z; Dereziński T; Czupryniak L
Oncotarget; 2017 Sep; 8(40):66940-66950. PubMed ID: 28978007
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for cancer development in type 2 diabetes: A retrospective case-control study.
Dąbrowski M; Szymańska-Garbacz E; Miszczyszyn Z; Dereziński T; Czupryniak L
BMC Cancer; 2016 Oct; 16(1):785. PubMed ID: 27724912
[TBL] [Abstract][Full Text] [Related]
3. Glycated hemoglobin, diabetes treatment and cancer risk in type 2 diabetes. A case-control study.
Dąbrowski M
Ann Agric Environ Med; 2013; 20(1):116-21. PubMed ID: 23540224
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
Yurgin N; Secnik K; Lage MJ
Clin Ther; 2007 Feb; 29(2):316-25. PubMed ID: 17472823
[TBL] [Abstract][Full Text] [Related]
5. Association Between Antidiabetic Medications and Prostate-Specific Antigen Levels and Biopsy Results.
Beckmann K; Crawley D; Nordström T; Aly M; Olsson H; Lantz A; Binti Abd Jalal N; Garmo H; Adolfsson J; Eklund M; Van Hemelrijck M
JAMA Netw Open; 2019 Nov; 2(11):e1914689. PubMed ID: 31693126
[TBL] [Abstract][Full Text] [Related]
6. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
7. Type 2 diabetes mellitus, glycemic control, and cancer risk.
Onitilo AA; Stankowski RV; Berg RL; Engel JM; Glurich I; Williams GM; Doi SA
Eur J Cancer Prev; 2014 Mar; 23(2):134-40. PubMed ID: 23962874
[TBL] [Abstract][Full Text] [Related]
8. [Obesity as a factor in the development of cancer in type 2 diabetes].
Łukasiewicz D; Chodorowska M; Jakubowska I
Pol Merkur Lekarski; 2015 Mar; 38(225):135-9. PubMed ID: 25815612
[TBL] [Abstract][Full Text] [Related]
9. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
Kautzky-Willer A; Kamyar MR; Gerhat D; Handisurya A; Stemer G; Hudson S; Luger A; Lemmens-Gruber R
Gend Med; 2010 Dec; 7(6):571-83. PubMed ID: 21195357
[TBL] [Abstract][Full Text] [Related]
10. Effect of metformin on the risk of prostate cancer in patients with type 2 diabetes by considering different confounding factors: a meta-analysis of observational studies.
Wang Y; Liu X; Yan P; Tang J; Chen T; Sun Y; Zhou W; Bi Y; Zhang ZJ
Eur J Cancer Prev; 2020 Jan; 29(1):42-52. PubMed ID: 30950925
[TBL] [Abstract][Full Text] [Related]
11. Sex differences in the influence of type 2 diabetes (T2D)-related genes, parental history of T2D, and obesity on T2D development: a case-control study.
Berumen J; Orozco L; Gallardo-Rincón H; Rivas F; Barrera E; Benuto RE; García-Ortiz H; Marin-Medina M; Juárez-Torres E; Alvarado-Silva A; Ramos-Martinez E; MartÍnez-Juárez LA; Lomelín-Gascón J; Montoya A; Ortega-Montiel J; Alvarez-Hernández DA; Larriva-Shad J; Tapia-Conyer R
Biol Sex Differ; 2023 Jun; 14(1):39. PubMed ID: 37291636
[TBL] [Abstract][Full Text] [Related]
12. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
13. Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score-Matched Study.
Lee YHA; Zhou J; Hui JMH; Liu X; Lee TTL; Hui K; Chan JSK; Wai AKC; Wong WT; Liu T; Ng K; Lee S; Dee EC; Zhang Q; Tse G
J Natl Compr Canc Netw; 2022 Jun; 20(6):674-682.e15. PubMed ID: 35714677
[TBL] [Abstract][Full Text] [Related]
14. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: a population-based case-control study.
Lin E; Garmo H; Van Hemelrijck M; Adolfsson J; Stattin P; Zethelius B; Crawley D
BMC Cancer; 2020 Jun; 20(1):551. PubMed ID: 32539807
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer-specific Survival After Radical Prostatectomy Is Improved Among Metformin Users but Not Among Other Antidiabetic Drug Users.
Joentausta RM; Rannikko A; Murtola TJ
Eur Urol Open Sci; 2021 Dec; 34():86-93. PubMed ID: 34934970
[TBL] [Abstract][Full Text] [Related]
16. Metformin and breast and gynecological cancer risk among women with diabetes.
Soffer D; Shi J; Chung J; Schottinger JE; Wallner LP; Chlebowski RT; Lentz SE; Haque R
BMJ Open Diabetes Res Care; 2015; 3(1):e000049. PubMed ID: 25664181
[TBL] [Abstract][Full Text] [Related]
17. Metformin and the risk of head and neck cancer: a case-control analysis.
Becker C; Jick SS; Meier CR; Bodmer M
Diabetes Obes Metab; 2014 Nov; 16(11):1148-54. PubMed ID: 25041125
[TBL] [Abstract][Full Text] [Related]
18. Short-term antidiabetic treatment with insulin or metformin has a similar impact on the components of metabolic syndrome in women with gestational diabetes mellitus requiring antidiabetic agents: results of a prospective, randomised study.
Zawiejska A; Wender-Ozegowska E; Grewling-Szmit K; Brazert M; Brazert J
J Physiol Pharmacol; 2016 Apr; 67(2):227-33. PubMed ID: 27226182
[TBL] [Abstract][Full Text] [Related]
19. Relation between diabetes, metformin treatment and the occurrence of malignancies in a Belgian primary care setting.
Geraldine N; Marc A; Carla T; Chantal M; Stefaan B; Welcome W; Frank B
Diabetes Res Clin Pract; 2012 Aug; 97(2):331-6. PubMed ID: 22386769
[TBL] [Abstract][Full Text] [Related]
20. Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus.
Lee RH; Sloane R; Pieper C; Lyles KW; Adler RA; Van Houtven C; LaFleur J; Colón-Emeric C
J Bone Miner Res; 2019 Nov; 34(11):2045-2051. PubMed ID: 31269274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
